Commisso Lab

Research focus

NIH R01 · 2024

Discovery of Novel Inhibitors Targeting trans-Golgi Network Acidification in Pancreatic Cancer

PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer-related deaths in the United States by 2030. With a 5-year relative survival rate of just 10%, PDAC has the highest death rate among the most common cancers, underscoring the urgent need for new therapeutic strategies that improve clinical outcomes. Recent years have witnessed a growing appreciation of the role that metabolic reprogramming plays in conferring survival advantages to PDAC cells, and the targeting of metabolic processes is considered a promising area for the development of novel therapies. In contrast to normal cells, cancer cells favor glycolysis for energy…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.